Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871236 | 0.85 | SLC5A2 (0.42) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2871442 | 0.82 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL13979885 | 0.81 | SLC5A2 (0.48) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2869962 | 0.81 | SLC5A1 (0.51) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19227119 | 0.81 | SLC5A2 (0.51) | SLC5A2SLC5A1GAA | |
| SCHEMBL13979827 | 0.80 | SLC5A2 (0.47) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL37715 | 0.80 | SLC5A2 (0.47) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15308138 | 0.80 | SLC5A2 (0.47) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL27820548 | 0.79 | SLC5A2 (0.46) | SLC5A2SLC5A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29220739 | 0.78 | IDO1 (0.39) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | SLC5A2 1771/4885SLC5A1 1236/4885SLC6A2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.